Your browser doesn't support javascript.
loading
Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options.
Shao, Spencer H; Allen, Brian; Clement, Jessica; Chung, Gina; Gao, Jingjing; Hubbell, Earl; Liu, Minetta C; Swanton, Charles; Tang, W H Wilson; Yimer, Habte; Tummala, Mohan.
Afiliación
  • Shao SH; Compass Oncology, Portland, OR, USA.
  • Allen B; GRAIL, LLC, a subsidiary of Illumina Inc., Menlo Park, CA, USA†.
  • Clement J; Hartford Healthcare, Hartford, CT, USA.
  • Chung G; The Christ Hospital Health Network, Cincinnati, OH, USA.
  • Gao J; GRAIL, LLC, a subsidiary of Illumina Inc., Menlo Park, CA, USA†.
  • Hubbell E; GRAIL, LLC, a subsidiary of Illumina Inc., Menlo Park, CA, USA†.
  • Liu MC; Mayo Clinic, Rochester, MN, USA.
  • Swanton C; The Francis Crick Institute, London, UK.
  • Tang WHW; University College London Cancer Institute, London, UK.
  • Yimer H; Cleveland Clinic, Cleveland, OH, USA.
  • Tummala M; Texas Oncology/USON, Tyler, USA.
Tumori ; 109(3): 335-341, 2023 Jun.
Article en En | MEDLINE | ID: mdl-36316952
There are four solid tumors with common screening options in the average-risk population aged 21 to 75 years (breast, cervical, colorectal, and, based on personalized risk assessment, prostate), but many cancers lack recommended population screening and are often detected at advanced stages when mortality is high. Blood-based multi-cancer early detection tests have the potential to improve cancer mortality through additional population screening. Reported here is a post-hoc analysis from the third Circulating Cell-free Genome Atlas substudy to examine multi-cancer early detection test performance in solid tumors with and without population screening recommendations and in hematologic malignancies. Participants with cancer in the third Circulating Cell-free Genome Atlas substudy analysis were split into three subgroups: solid screened tumors (breast, cervical, colorectal, prostate), solid unscreened tumors, and hematologic malignancies. In this post hoc analysis, sensitivity is reported for each subgroup across all ages and those aged ⩾50 years overall, by cancer, and by clinical cancer stage. Aggregate sensitivity in the solid screened, solid unscreened, and hematologic malignancy subgroups was 34%, 66%, and 55% across all cancer stages, respectively; restricting to participants aged ⩾50 years showed similar aggregate sensitivity. Aggregate sensitivity was 27%, 53%, and 60% across stages I to III, respectively. Within the solid unscreened subgroup, aggregate sensitivity was >75% in 8/18 cancers (44%) and >50% in 13/18 (72%). This multi-cancer early detection test detected cancer signals at high (>75%) sensitivity for multiple cancers without existing population screening recommendations, suggesting its potential to complement recommended screening programs.Clinical trial identifier: NCT02889978.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Neoplasias Hematológicas Tipo de estudio: Diagnostic_studies / Guideline / Screening_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Tumori Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Neoplasias Hematológicas Tipo de estudio: Diagnostic_studies / Guideline / Screening_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Tumori Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos